Equitable Trust Co. Sells 11,792 Shares of Harrow, Inc. $HROW

Equitable Trust Co. trimmed its holdings in Harrow, Inc. (NASDAQ:HROW) by 21.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,243 shares of the company’s stock after selling 11,792 shares during the period. Equitable Trust Co.’s holdings in Harrow were worth $2,083,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. New York State Common Retirement Fund lifted its holdings in shares of Harrow by 1,944.7% during the 3rd quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock valued at $10,300,000 after purchasing an additional 203,333 shares in the last quarter. Diametric Capital LP acquired a new stake in Harrow during the 2nd quarter worth approximately $4,748,000. Bank of America Corp DE lifted its stake in Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock valued at $6,519,000 after buying an additional 155,258 shares in the last quarter. Divisadero Street Capital Management LP acquired a new position in shares of Harrow in the second quarter valued at approximately $4,293,000. Finally, Invesco Ltd. boosted its holdings in shares of Harrow by 967.6% in the second quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock valued at $4,610,000 after buying an additional 136,809 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Down 0.9%

Harrow stock opened at $51.55 on Tuesday. The firm has a 50-day moving average of $47.85 and a 200-day moving average of $43.17. Harrow, Inc. has a one year low of $20.85 and a one year high of $54.85. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -515.45 and a beta of 0.07.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. HC Wainwright raised their price objective on shares of Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. LADENBURG THALM/SH SH lifted their price target on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $94.00 target price on shares of Harrow in a research report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.43.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.